Immunocore
Presence
Acquisition, funding and merger involving Immunocore.
- Immunocore becomes a unicorn with its fundraising of $140 Million. (posted on July 21 2022).
Executives
View the org chart displaying its 28 main executives
Most searched biographies at Immunocore
- Bahija Jallal, Chief Executive Officer and Director
- Travis Coy, Non-Executive Director
- John Bell, Non Executive Chairman of the Board
Create your alert
to follow the executive moves at Immunocore.
Biotechnology
Immunocore has 2,275 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (posted on April 16 2024).
- Nurix Therapeutics has just announced a $175 Million fundraising (posted on April 13 2024).
Popular contacts in Biotechnology
News
Press releases by Immunocore
- Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine :: Immunocore PLC
- Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial :: Immunocore PLC
- Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021 :: Immunocore PLC
- Immunocore to present at upcoming investor conferences :: Immunocore PLC
- Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma :: Immunocore PLC
- Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma :: Immunocore PLC
- Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update :: Immunocore PLC
- Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting :: Immunocore
- Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B :: Immunocore
- Immunocore Reports First Quarter 2021 Financial Results :: Immunocore
- View more press releases Close
Social media about Immunocore
- Immunocore on Wikipedia, Google News & Yahoo Finance
- Immunocore on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Bahija Jallal 
